ARCHITECT Anti-HCV Reagents

Notice type: Advisory

Date: 15/04/2010

 

Product name or type:
ARCHITECT Anti-HCV Reagents


Reference:
SN2010(02)


Manufacturer Or Supplier:
Abbott GmbH & Co. KG.


Target Audience:
Hospital Risk Managers 
Hospital Laboratories 

Please bring this safety notice to the attention of all who need to be aware of it.


Problem Or Issue:

Abbott has determined that S/CO values generated with ARCHITECT Anti-HCV (LN 6C37) may decrease when 25% or less of test volume is remaining leading to: 

• Abbott Positive Control values shift down and/or out of range low,

• Non-Abbott Positive Control values shift down and/or out of range low, and/or

• A decrease in patient result values



Background Information Or Related Documents:

Abbott informed the Irish Medicines Board (IMB) that the above issue was identified through customer complaints and confirmed by internal complaint investigations. 

Abbott has advised the IMB that internal studies have shown a maximum downward shift of 40% for the positive control. Abbott has indicated that the drop in S/CO is due to an inhomogeneity within the assay diluent. 

It has been confirmed that patient samples may show a decrease in S/CO values comparable to the positive control. This may result in false negative results for low reactive patient samples. 

The investigation into the root cause of this issue is ongoing. 


ARCHITECT Anti-HCV Reagents Document


Actions To Be Taken:

Abbott has issued a Field Safety Notice (FSN) (March 2010) to all Irish customers using the ARCHITECT Anti-HCV assay recommending customers mix the ARCHITECT Anti-HCV assay diluent (LN 6C37J, green bottle label) prior to testing each day of use. 



Further Information:
IMB RECOMMENDATIONS
The IMB is advising customers to consider the need to conduct a look back study. 

The manufacturer has confirmed that all lots from 67599HN00 may be affected by this issue and that they cannot guarantee that previous lots that have since expired were not affected. 

Abbott has advised the IMB that samples below 0.6 S/CO do not have an increased risk for false negative results as Abbott has observed a maximum drop of 40% (0.4 S/CO for a sample running at 1.0 S/CO with a positive interpretation).

The IMB recommends that customers who determine the need to conduct a look back study and require further information related to the product issue contact Abbott for further advice. 

Enquiries to the manufacturer should be addressed to: 

Abbott Diagnostics 
Unit 4051 Kingswood Drive 
Citywest Business Campus 
Dublin 24 

Telephone: +353 1 4691561 
Fax: +353 1 4691565 
E-mail: tara.mcgrath@abbott.com 

ENQUIRIES 

All adverse incidents relating to a medical device should be reported to the: 

Human Products Safety Monitoring Department 
Health Products Regulatory Authority 
Kevin O’Malley House 
Earlsfort Centre 
Earlsfort Terrace 
Dublin 2 

Telephone: +353-1-6764971 
Fax: +353-1-6344033 


PDF Version: Download


« Back